Evidence map›Paper›PMID 26038707›Full record

ArticlePharmacology research & perspectives2015

A novel 2-decenoic acid thioester ameliorates corticosterone-induced depression- and anxiety-like behaviors and normalizes reduced hippocampal signal transduction in treated mice.

Shoyo Shibata, Munekazu Iinuma, Hitomi Soumiya, Hidefumi Fukumitsu, Yoshiko Furukawa, Shoei Furukawa

Open access · goldAbstract read
In one paragraph

Article in Pharmacology research & perspectives, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shoyo ShibataLaboratory of Molecular Biology, Department of Biofunctional Analysis, Gifu Pharmaceutical University Daigaku-nishi 1-25-4, Gifu, 501-1196, Japan.
Munekazu IinumaLaboratory of Pharmacognosy, Department of Bioactive Molecules, Gifu Pharmaceutical University Daigaku-nishi 1-25-4, Gifu, 501-1196, Japan.
Hitomi SoumiyaLaboratory of Molecular Biology, Department of Biofunctional Analysis, Gifu Pharmaceutical University Daigaku-nishi 1-25-4, Gifu, 501-1196, Japan.
Hidefumi FukumitsuLaboratory of Molecular Biology, Department of Biofunctional Analysis, Gifu Pharmaceutical University Daigaku-nishi 1-25-4, Gifu, 501-1196, Japan.
Yoshiko FurukawaDepartment of Pharmaceutical Pharmacology, Faculty of Pharmaceutical Sciences, Matsuyama University Bunkyo-cho 4-2, Matsuyama, Ehime, 790-8578, Japan.
Shoei FurukawaLaboratory of Molecular Biology, Department of Biofunctional Analysis, Gifu Pharmaceutical University Daigaku-nishi 1-25-4, Gifu, 501-1196, Japan.
Gifu Pharmaceutical University · JPMatsuyama University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We characterized mice administered corticosterone (CORT) at a dose of 20 mg/kg for 3 weeks to determine their suitability as a model of mood disorders and found that the time immobilized in the tail suspension test was longer and the time spent in the open arms of the elevated plus-maze test was shorter than those of the vehicle-treated group, findings demonstrating that chronic CORT induced both depression-like and anxiety-like behaviors. Furthermore, the levels of phosphorylated extracellular signal-regulated kinase (pERK) 1/2 in the hippocampus and cerebral cortex were reduced in the CORT-treated group. Using this model, we investigated the protective effect of the ester, thioester, and amide compounds of 2-decenoic acid derivatives (termed compounds A, B, and C, respectively). The potency of the protective activity against the CORT-induced depression-like or anxiety-like behaviors and the reduction in pERK1/2 level were found to be in the following order: compound B > compound C > compound A. Therefore, we further investigated the therapeutic activity of only compound B, and its effect on depression-like behavior was observed after oral administration for 1 or 2 weeks, and its effect on anxiety-like behavior was observed after oral administration for 3 weeks. The ratios of phosphorylated ERK1/2, Akt, and cAMP-response element-binding protein to their respective nonphosphorylated forms were smaller in the CORT-treated group than in the vehicle-treated group; however, subsequent treatment with compound B at either 0.3 or 1.5 mg/kg significantly ameliorated this reduction. Compound B appeared to elicit intracellular signaling, similar to that elicited by brain-derived neurotrophic factor, and its mode of action was shown to be novel and different from that of fluvoxamine, a currently prescribed drug for mood disorders.

Indexed as

2-decenoic acid thioesteranxiety-like behaviorcorticosteronedepression-like behaviorextracellular signal-regulated kinase (ERK) 1/2fluvoxamine

Identifiers

PMID26038707
PMCPMC4448981
OpenAlexW2086543548

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.